mCRC: Combination Therapy and Testing

Modern Treatment Approaches to Prostate CancerПодробнее

Resistance in BRAF and KRAS Mutant Cancers - by Ryan Corcoran, MD, PhDПодробнее

Differential treatment options for left- and right-sided mCRCПодробнее

5-FU FROM A TO Z: What You Need to Know about the Most Common Colorectal Cancer TreatmentПодробнее

Immunotherapy Combinations in MSI and MSS mCRCПодробнее

Debate: MSI High Colon Cancer - ImmunotherapyПодробнее

HER2 Testing in MetastaticColorectal Cancer (mCRC)Подробнее

Role of I/O Combination Therapies in mCRCПодробнее

Key Trials in mCRC: I/O Combination TherapiesПодробнее

Later-Line Therapy Innovations in MCRCПодробнее

Lack of Durable Responses in Current Treatment of mCRCПодробнее

Future Directions in Later Line Therapy for mCRCПодробнее

CheckMate142: Checkpoint combination therapy in first-line colorectal cancerПодробнее

The Role of Mutation Testing in mCRCПодробнее

Dr. Overman on Tailoring Approaches to Molecular Subsets in mCRCПодробнее

Updated analysis from MOUNTAINEER: tucatinib and trastuzumab for HER2-positive mCRCПодробнее

PanaMa: maintenance FU/FA with or without panitumumab in mCRCПодробнее

TACT-D: a randomized study evaluating tailoring of mCRC therapy using ctDNAПодробнее

Molecular Testing and First-Line Therapy in mCRCПодробнее

First- and Second-Line Treatment for mCRC in Specific PopulationsПодробнее